Usman Baber to Ticlopidine
This is a "connection" page, showing publications Usman Baber has written about Ticlopidine.
Connection Strength
3.973
-
Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study. JACC Cardiovasc Interv. 2017 10 23; 10(20):2017-2025.
Score: 0.568
-
Antiplatelet treatments: recent evidence from randomized controlled trials. Curr Opin Cardiol. 2017 Jul; 32(4):356-362.
Score: 0.565
-
Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study. Am Heart J. 2017 Jun; 188:73-81.
Score: 0.551
-
Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents. J Invasive Cardiol. 2010 Feb; 22(2):80-3.
Score: 0.338
-
Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. Can J Cardiol. 2018 03; 34(3):319-329.
Score: 0.146
-
Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease. Thromb Haemost. 2017 10 05; 117(10):1981-1988.
Score: 0.143
-
Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry). Am J Cardiol. 2017 Sep 15; 120(6):904-910.
Score: 0.141
-
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). Circ Cardiovasc Interv. 2017 02; 10(2).
Score: 0.137
-
Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. Am J Cardiol. 2016 Dec 01; 118(11):1661-1668.
Score: 0.134
-
Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. Catheter Cardiovasc Interv. 2017 Jun 01; 89(7):E217-E225.
Score: 0.134
-
Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity. Clin Pharmacol Ther. 2016 09; 100(3):287-94.
Score: 0.131
-
Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study. Catheter Cardiovasc Interv. 2017 Mar 01; 89(4):629-637.
Score: 0.131
-
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. J Am Coll Cardiol. 2016 May 17; 67(19):2224-2234.
Score: 0.130
-
Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin. Thromb Haemost. 2014 Nov; 112(5):1069-70.
Score: 0.115
-
Clustering of acute and subacute stent thrombosis related to the introduction of generic clopidogrel. J Cardiovasc Pharmacol Ther. 2014 Mar; 19(2):201-8.
Score: 0.110
-
An allele-specific PCR system for rapid detection and discrimination of the CYP2C19*4A, *4B, and *17 alleles: implications for clopidogrel response testing. J Mol Diagn. 2013 Nov; 15(6):783-9.
Score: 0.108
-
Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity. Thromb Haemost. 2013 Jul; 110(1):118-23.
Score: 0.106
-
High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. JACC Cardiovasc Imaging. 2012 May; 5(5):540-9.
Score: 0.099
-
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. Am Heart J. 2017 Feb; 184:81-87.
Score: 0.034
-
Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition study. J Thromb Thrombolysis. 2016 Aug; 42(2):186-96.
Score: 0.033
-
Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis. JACC Cardiovasc Interv. 2016 05 23; 9(10):1036-46.
Score: 0.033
-
Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. Am J Cardiol. 2016 Jun 15; 117(12):1877-83.
Score: 0.032
-
Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome? Curr Opin Cardiol. 2014 Jul; 29(4):301-6.
Score: 0.029
-
Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary "real-world" practice. J Interv Cardiol. 2012 Oct; 25(5):482-92.
Score: 0.025